XML 62 R37.htm IDEA: XBRL DOCUMENT
v3.25.4

PRODUCT REVENUE AND PROVISIONS FOR VARIABLE CONSIDERATION (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2025
Revenue from Contract with Customer [Abstract] |
Schedule of Product Revenues | The following table presents net product revenue for Vafseo and Auryxia (in thousands):
|  | Years Ended December 31,
Product |  | 2025 |  | 2024 |  | 2023
Vafseo |  | $ | 45,790 |  |  | $ | — |  |  | $ | — |
Auryxia(1) |  | 181,542 |  |  | 152,180 |  |  | 170,301 |
Total product revenues |  | $ | 227,332 |  |  | $ | 152,180 |  |  | $ | 170,301 |
(1) Includes the authorized generic version of Auryxia sold and distributed by the Company's authorized generic distribution partner, Mylan Therapeutics, Inc., or AG Distributor, during the year ended December 31, 2025.
Schedule of Changes in Contract Assets and Liabilities | The following table presents changes in the Company’s contract assets and liabilities related to the Company's sales to its AG Distributor (in thousands):
|  | Year Ended December 31, 2025
|  | Balance at Beginning of Period |  | Additions |  | Deductions |  | Balance at End of Period
Contract assets: |  |  |  |  |  |  |  |
Accounts receivable |  | $ | — |  |  | $ | 12,006 |  |  | $ | (11,812) |  |  | $ | 194 |
Contract liabilities: |  |  |  |  |  |  |  |
Deferred revenue |  | $ | — |  |  | $ | 10,675 |  |  | $ | (7,994) |  |  | $ | 2,681 |
The following table presents changes in the Company’s contract assets and liabilities related to license, collaboration and other revenue agreements (in thousands):
| Year Ended December 31, 2025
| Balance at Beginning of Period |  | Additions |  | Deductions |  | Balance at End of Period
Contract assets: |  |  |  |  |  |  |
Accounts receivable(1) | $ | 2,010 |  |  | $ | 8,894 |  |  | $ | (8,513) |  |  | $ | 2,391 |
Contract liability: |  |  |  |  |  |  |
Deferred revenue | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |
| Year Ended December 31, 2024
| Balance at Beginning of Period |  | Additions |  | Deductions |  | Balance at End of Period
Contract assets: |  |  |  |  |  |  |
Accounts receivable(1) | $ | 3,333 |  |  | $ | 8,562 |  |  | $ | (9,885) |  |  | $ | 2,010 |
Contract liabilities: |  |  |  |  |  |  |
Deferred revenue (long-term)(2) | $ | 43,296 |  |  | $ | — |  |  | $ | (43,296) |  |  | $ | — |
(1)Excludes accounts receivable from product sales of Auryxia and Vafseo which are included in the accompanying consolidated balance sheets as of December 31, 2025 and 2024. (2)See Note 8, Liability Related to Settlement Royalties, Working Capital Fund Liability and Liability Related to Sale of Future Royalties, for further information.
Schedule of Product Revenue Allowance and Provision Categories | Product revenue allowance and provision categories were as follows:
(in thousands) |  | Chargebacks and Discounts |  | Rebates, Fees and other Deductions |  | Returns |  | Total
Balance at December 31, 2022 |  | $ | 1,259 |  |  | $ | 26,252 |  |  | $ | 10,923 |  |  | $ | 38,434 |
Provisions related to sales in current year |  | 11,138 |  |  | 79,648 |  |  | 6,181 |  |  | $ | 96,967 |
Adjustments related to prior year sales |  | (304) |  |  | (1,506) |  |  | 1,648 |  |  | $ | (162) |
Credits/payments made |  | (10,486) |  |  | (81,403) |  |  | (11,836) |  |  | $ | (103,725) |
Balance at December 31, 2023 |  | $ | 1,607 |  |  | $ | 22,991 |  |  | $ | 6,916 |  |  | $ | 31,514 |
Current provisions related to sales in current year |  | 9,225 |  |  | 44,914 |  |  | 4,862 |  |  | 59,001 |
Adjustments related to prior year sales |  | (94) |  |  | (2,056) |  |  | (540) |  |  | (2,690) |
Credits/payments made |  | (9,302) |  |  | (50,123) |  |  | (4,796) |  |  | (64,221) |
Balance at December 31, 2024 |  | $ | 1,436 |  |  | $ | 15,726 |  |  | $ | 6,442 |  |  | $ | 23,604 |
Current provisions related to sales in current year |  | 4,051 |  |  | 81,019 |  |  | 634 |  |  | 85,704 |
Adjustments related to prior year sales |  | 69 |  |  | 143 |  |  | (1,631) |  |  | (1,419) |
Credits/payments made |  | (4,403) |  |  | (24,299) |  |  | (2,094) |  |  | (30,796) |
Balance at December 31, 2025 |  | $ | 1,153 |  |  | $ | 72,589 |  |  | $ | 3,351 |  |  | $ | 77,093 |

X
- Definition Schedule Of Product Revenue Allowance And Reserve Categories. + References No definition available. + Details
Name: | akba_ScheduleOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock
Namespace Prefix: | akba_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 + Details
Name: | us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration